Navigation Links
Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry'

PharmaVOICE magazine cites Dr. Lanza for 'Courage Under Fire'

WORCESTER, Mass., Aug. 21 /PRNewswire-FirstCall/ -- Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC) is proud to announced that Dr. Robert Lanza, the company's Vice President of Research and Scientific Development, has been recognized for his research and contributions to stem cell science and technology in the current issue of PharmaVOICE (cover story July/August issue). Dr. Lanza is one of only five researchers and scientists to be acknowledged for his discoveries "behind the medicines making a significant impact on the pipelines of today and of the future."

"Though his work has sometimes been attacked by political and religious establishments, Robert Lanza, M.D., forges ahead with research based on the right thing to do scientifically," PharmaVOICE stated. "Dr. Lanza is boldly leading Advanced Cell Technology's team of scientists toward bringing the benefits of human embryonic stem cell (hESC) technology to the tens of millions of people worldwide who are suffering from a host of degenerative diseases and other conditions," the journal continued. "Committed to the science, Dr. Lanza believes treatments using hESCs have the potential to eventually offer not just treatments, but actual cures for Parkinson's disease, macular degeneration, heart disease, and a whole host of other debilitating diseases .... Inspired by enlightened thinkers and human kindness, Dr. Lanza believes in the mission of advancing research, and he is looking forward to the next goal: to start human clinical trials using embryonic stem cells."

"We are pleased that highly regarded journals such as PharmaVOICE continue to recognize the contributions and achievements of our researchers," remarked William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Moreover, we are excited by the novel therapies our research may yield to treat indications that have few alternatives."

Over the past year, Advanced Cell Technology has made significant progress in its RPE (retinal pigment epithelium) and its HG (hemangioblast) programs to treat degenerative retinal disorders and cardiovascular disease, and expects to file INDs for both programs by the end of 2008. Furthermore, the company announced last month that it had entered into a definitive merger agreement to acquire autologous adult stem cell company Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. Mytogen has successfully completed Phase I clinical trials and will begin Phase II trials after the merger with ACT. Upon the transaction's closing, Advanced Cell Technology will transition from a development stage to a clinical stage company.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, visit

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE Advanced Cell Technology, Inc.
Copyright©2007 PR Newswire.All rights reserved

Related biology technology :

1. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
2. Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option
3. 384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler
4. WARF expands license agreement with Advanced Cell Technology
5. Rockwells $1M gift to UWM will support advanced automation research
6. Advanced CIO: Technology execs must trumpet their success
7. FDA approves advanced digital mammography system
8. Tech Digest: Inacom; St. Michaels, St. Clares hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield
9. Wisconsins insurance companies use advanced IT to speed relief
10. $60 Million Available in Advanced Tech Competition
11. Advanced Life Sciences to Hit the Road For $30 Million in Funding
Post Your Comments:
(Date:10/12/2015)... cell surface marker detection market ... to a new report by Grand View Research, Inc. This ... of oncology diseases and other cell-associated disorders. --> ... USD 6.49 billion by 2022, according to a new report ... be attributed to rise in incidence of oncology diseases and ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... 12, 2015 VolitionRx Limited (NYSE MKT: ... study of its NuQ ® blood-based test for early ... of Clinical Epigenetics , the official journal of the ... with Lund University, Sweden ... PhD, Professor of Surgery and Vice-Dean, Faculty of Medicine. ...
(Date:10/12/2015)... ... October 12, 2015 , ... LifeTrak , a leader in ... Zoom, the world’s first amphibious fitness tracker that seeks to meet the needs of ... accurate heart rate monitoring both in water and on land, making it ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) ... Recognition Market by Component (Hardware & Software), Product ... Industry (Travel & Immigration, Military & Defense, & ... report to their offering. ... Market worth 3627.90 Million USD by 2020 ...
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/7/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... long- term executive at American Express has been appointed ... ) ("NXT-ID" or the "Company"), a biometric authentication company ... of the Wocket® smart wallet announces Mr. Stanley ...
Breaking Biology News(10 mins):